ClinicalTrials.gg
Active, not recruitingNCT05121090ELIPSEUpdated Apr 22, 2026

Lille Study for Childhood Health Promotion

An observational study in Overweight, Infant, Overweight and Obesity and Overweight, Childhood, sponsored by University Hospital, Lille. Active, not recruiting at 1 site in France. Open to participants aged 5 Years to 6 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by University Hospital, Lille · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
460
Ages
5 Years to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Pediatric Obesity with a site in France — 3 open to participants now, 4 under way, 1 of them phase 3. Pediatric Obesity · France.

Started
2022
the only one that year
Observational
9 of 26
2 open now
Registered
23rd of 26
by date

Among the 26 studies in Pediatric Obesity with a site in France, this one is the only one that started in 2022, is one of 9 observational ones, and was the 23rd registered.

Pediatric Obesity

1,132 studies on the registry are indexed under Pediatric Obesity; 183 are open to participants now.

Browse Pediatric Obesity studies →

Open to participants now

3 of the 26 studies in Pediatric Obesity with a site in France are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 119 Pediatric Obesity studies recruiting now, 16 (13%) set no upper age limit and 101 (85%) stop at 75 or younger; 110 take children under 18; 67 take healthy volunteers.

This study: 5 Years to 6 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Pediatric Obesity with a site in France, or all of them as a file.
02

Study summary

Obesity could be avoided but once declared it become a chronic disease with numerous health complications, including cardiovascular and metabolic diseases, cancers, and finally a loss of life expectancy. Considering that after the age of 6 years old, half of the obese children will become obese adults, the WHO has been declared childhood obesity prevention as a health priority area. Large-scale prevention of obesity is challenging and it would be more efficient to proceed to early identification of high risks children to implement personalized prevention.

The ELIPSE study main objective is to evaluate the efficacy of personalized multidisciplinary care to reduce the BMI of overweight or obese children. A 2 years educational program will be evaluated at short and longer terms (after a 12 months follow-up), and its benefits will also be assessed based on comparison with a historical control group.

Along with efficacy evaluation, scientific objectives were designed to investigate clinical, genetic, social, and behavioural risk factors and to analyse potential correlations between these factors and a predisposition to overweight or obesity. Moreover, advanced analyses will be performed to decipher the impact of diverse risk profiles on the efficacy of the educational program.

The motive of the ELIPSE study is to promote the health and well-being of children and their families to tackle the health burden represented by childhood overweight and obesity. Combined with innovative scientific objectives, this study ambitions to develop more efficient and more personalized preventive care methods.

03

Conditions studied

  • Overweight, Infant
  • Overweight and Obesity
  • Overweight, Childhood

Keywords

  • Paediatric overweight and obesity
  • Childhood obesity
  • Personalized prevention and medicine
  • Educational program
  • Genetic of obesity
04

Who can participate

Ages eligible
5 Years to 6 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Children from the first year of primary school in Lille City

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children from the first year of primary school in Lille City
  • Overweight or obese children as defined by the IOTF and/or with at least one of the following risk factors: 1) early adiposity rebound (before 6 years old), 2) an upward crossing of major percentiles on the curve (after 6 years old).
  • Children whose legal tutor(s) is(are) able to understand the enlightened information.
  • Children whose legal tutor(s) has(ve) signed the free and .

Exclusion criteria

Exclusion Criteria:

  • Refusal from children or their tutors to participate in the study.
  • Impossibility to participate in the study in its totality.
  • Pathology known to impact the : follow-up care for eating behaviour problems, endocrine disorders (hypercorticism, hypothyroidism, growth factor deficiency, hypothalamic-hypophysis lesions), genetic disorders (Prader Willi syndrome, Bardet-Biedl syndrome), drugs that affect body weight (antidepressant, neuroleptics, corticoids).
  • Previous participation in a similar educational program.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
460 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • BehavioralEducational program

    The educational program is based on dietary, physical activity, psychology, and sophrology approaches dispensed by health care professionals. Evaluations will consist of anthropometric measurements (height, weight, body mass index), behavioural questionnaires, and basic physical tests (handgrip, squats, balance, …). Optionally, a saliva collection will be proposed to obtain the DNA required for genetic analyses.

06

What researchers measure

Primary outcomes

  1. Changes in BMI Z-score

    The objective is to estimate the mean variation of the BMI Z-score between the inclusion and the end of the educational program, after 2 years. Body mass index z score is based on previous results, estimate that the BMI Z-score will be decreased by 0.3 +/- 0.6 SD.

    Time frame: At the end of the educational program, an average of 2 years after inclusion

Secondary outcomes

  1. BMI Z-score between children included in the study and a historical control group

    At the end of the educational program (2 years after inclusion), BMI Z-scores of children who completed the study will be compared to those of a historical control group composed of children of similar ages who did not benefit from an educational program

    Time frame: At the end of the educational program, an average of 2 years after inclusion

  2. Changes in BMI Z-score.

    The objective is to estimate the mean variation of the BMI Z-score between the inclusion and the end of the educational program follow-up, 3 years after inclusion.

    Time frame: At the end of the educational program follow-up, an average of 3 years after inclusion

  3. Correlation between clinical and environmental variables and changes in BMI Z-score

    The objective is to study the statistical relationship between the BMI Z-score and clinical and environmental variables: birth weight (kg), mother's BMI (kg/m\^2), gestationnel diabetes, parental weight loss surgery, number of child(ren) in the family, socioeconomic status evaluated by the parents socio-professional category (french indices), smoking during pregrancy)

    Time frame: At the end of the educational program, an average of 2 years after inclusion

  4. Impact of polygenic risk scores of obesity on changes in BMI Z-score

    A multi-variants analysis will be performed using DNA chips to identify loci associated with an increase of the BMI to obtained a polygenic risk score. This score will then be included as a variable for the analyses of the secondary outcome

    Time frame: Through study completion, an average of 3 years after inclusion

  5. Impact of rare pathogenic mutations causing obesity on changes in BMI Z-score.

    A whole-exome sequencing will be performed, followed by the identification of rare mutations involved in obesity or novel genes

    Time frame: Through study completion, an average of 3 years after inclusion

07

Study locations

1 site
  • Association PrevSanté MEL
    Lille, 59000, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2022 (actual). Primary completion is estimated for Apr 2027, 63 months after the start.

Of 94 non-industry observational studies under Pediatric Obesity, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 132. This study's planned 63 months is above that.

Counting every sponsor, half of 96 studies reached it within 52 months; a quarter within 21 and three quarters within 157.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2021
First posted
Nov 16, 2021
StartActual
Jan 19, 2022
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2027
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05121090
Collaborators
National Center for Precision Diabetic Medicine,PreciDIAB, PrevSanté MEL, APESAL, National Research Agency, France, European Union, Hauts-de-France Regional Council, University of Lille Nord de France, Groupement des Hôpitaux de l'Institut Catholique de Lille
Responsible party
Sponsor
First posted
Nov 16, 2021
Start date
Jan 19, 2022
Primary completion
Apr 2027 (estimated)
Completion
Apr 2027 (estimated)
Last update
Apr 22, 2026

Study contacts

Louise Montagne, MD
principal investigator · Lille Catholic University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion